Combigene Financials
| COMBI Stock | SEK 2.60 0.06 2.26% |
Combigene |
Understanding current and past Combigene Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Combigene's financial statements are interrelated, with each one affecting the others. For example, an increase in Combigene's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Combigene's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Combigene AB. Check Combigene's Beneish M Score to see the likelihood of Combigene's management manipulating its earnings.
Combigene Stock Summary
Combigene competes with Kancera AB, BioInvent International, Oncopeptides, and Acarix AS. CombiGene AB engages in the development and commercialization of gene therapy for the treatment of neurological and psychiatric disorders. CombiGene AB was founded in 1999 and is headquartered in Lund, Sweden. Combigene operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 7 people.| Instrument | Sweden Stock View All |
| Exchange | Stockholm Exchange |
| ISIN | SE0016101935 |
| Business Address | Agavagen 52A, Liding, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.combigene.com |
| Phone | 46 7 04 66 31 63 |
| Currency | SEK - Swedish Kronor |
You should never invest in Combigene without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Combigene Stock, because this is throwing your money away. Analyzing the key information contained in Combigene's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Combigene Key Financial Ratios
There are many critical financial ratios that Combigene's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Combigene AB reports annually and quarterly.Combigene Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Combigene's current stock value. Our valuation model uses many indicators to compare Combigene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Combigene competition to find correlations between indicators driving Combigene's intrinsic value. More Info.Combigene AB is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.43 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Combigene AB is roughly 2.31 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Combigene's earnings, one of the primary drivers of an investment's value.Combigene AB Systematic Risk
Combigene's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Combigene volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Combigene AB correlated with the market. If Beta is less than 0 Combigene generally moves in the opposite direction as compared to the market. If Combigene Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Combigene AB is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Combigene is generally in the same direction as the market. If Beta > 1 Combigene moves generally in the same direction as, but more than the movement of the benchmark.
Combigene December 12, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Combigene help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Combigene AB. We use our internally-developed statistical techniques to arrive at the intrinsic value of Combigene AB based on widely used predictive technical indicators. In general, we focus on analyzing Combigene Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Combigene's daily price indicators and compare them against related drivers.
| Downside Deviation | 6.75 | |||
| Information Ratio | 0.0268 | |||
| Maximum Drawdown | 51.27 | |||
| Value At Risk | (7.81) | |||
| Potential Upside | 9.02 |
Additional Tools for Combigene Stock Analysis
When running Combigene's price analysis, check to measure Combigene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Combigene is operating at the current time. Most of Combigene's value examination focuses on studying past and present price action to predict the probability of Combigene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Combigene's price. Additionally, you may evaluate how the addition of Combigene to your portfolios can decrease your overall portfolio volatility.